Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $320
Revolution Medicines
Revolution Medicines RVMD | 0.00 |
Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:
RVMD) with a Outperform and raises the price target from $230 to $320.
